Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GH 
Guardant Health Inc (GH)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: GH (3-star) is a STRONG-BUY. BUY since 12 days. Profits (10.07%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
24 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $61.33
1 Year Target Price $61.33
| 15 | Strong Buy |
| 6 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 17.38% | Avg. Invested days 24 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 8.04B USD | Price to earnings Ratio - | 1Y Target Price 61.33 |
Price to earnings Ratio - | 1Y Target Price 61.33 | ||
Volume (30-day avg) 24 | Beta 1.44 | 52 Weeks Range 20.14 - 67.51 | Updated Date 08/28/2025 |
52 Weeks Range 20.14 - 67.51 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.35 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-07-30 | When - | Estimate -0.72 | Actual -0.44 |
Profitability
Profit Margin -49.93% | Operating Margin (TTM) -45.75% |
Management Effectiveness
Return on Assets (TTM) -19.57% | Return on Equity (TTM) -4584.47% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 8744794600 | Price to Sales(TTM) 9.7 |
Enterprise Value 8744794600 | Price to Sales(TTM) 9.7 | ||
Enterprise Value to Revenue 10.4 | Enterprise Value to EBITDA -5.4 | Shares Outstanding 124706000 | Shares Floating 119555505 |
Shares Outstanding 124706000 | Shares Floating 119555505 | ||
Percent Insiders 4.5 | Percent Institutions 98.98 |
Upturn AI SWOT
Guardant Health Inc
Company Overview
History and Background
Guardant Health was founded in 2012. It focuses on developing non-invasive cancer tests using liquid biopsies. The company's initial focus was on advanced-stage cancer, but has expanded to early-stage detection and recurrence monitoring.
Core Business Areas
- Precision Oncology Testing: Offers comprehensive genomic profiling services for advanced cancer patients to help physicians select appropriate therapies. This includes Guardant360 and Guardant360 CDx.
- Early Cancer Detection: Developing blood tests for early detection of cancer in high-risk individuals. This includes the Shield test.
- Development Partnerships: Collaborates with pharmaceutical companies to develop companion diagnostics and support clinical trials.
Leadership and Structure
Helmy Eltoukhy (CEO), AmirAli Talasaz (President and Co-CEO). Operates with a typical corporate structure, with departments focused on research, development, commercial operations, and finance.
Top Products and Market Share
Key Offerings
- Guardant360 CDx: A comprehensive liquid biopsy test for advanced-stage cancer patients. It identifies genomic alterations to help guide treatment decisions. Competitors include Foundation Medicine (FMI) and Roche.
- Guardant Reveal: A liquid biopsy test for detecting minimal residual disease (MRD) and monitoring recurrence. Competitors include Natera (NTRA) and Adaptive Biotechnologies (ADPT).
- Shield: A blood test designed for early cancer detection. It is intended for screening average-risk individuals. Competitors include Exact Sciences (EXAS) and Grail (acquired by Illumina).
Market Dynamics
Industry Overview
The liquid biopsy market is rapidly growing due to its potential for non-invasive cancer diagnostics and personalized medicine. Key drivers include advances in genomics, increasing cancer incidence, and demand for less invasive diagnostic methods.
Positioning
Guardant Health is a leader in the liquid biopsy market, particularly in advanced-stage cancer testing. It aims to expand its reach into early cancer detection and recurrence monitoring. Competitive advantages include its established brand, comprehensive testing platform, and extensive clinical data.
Total Addressable Market (TAM)
The total addressable market for liquid biopsy is estimated to be in the tens of billions of dollars. Guardant Health is positioned to capture a significant portion of this market by expanding its product offerings and targeting different stages of cancer care.
Upturn SWOT Analysis
Strengths
- Leading market position in liquid biopsy
- Comprehensive testing platform
- Strong brand recognition
- Extensive clinical data
- Established relationships with pharmaceutical companies
Weaknesses
- High operating expenses
- Dependence on reimbursement from payers
- Competition from larger diagnostic companies
- Regulatory uncertainty
Opportunities
- Expanding into early cancer detection
- Increasing adoption of liquid biopsy in clinical practice
- Developing new biomarkers and tests
- Partnering with pharmaceutical companies to develop companion diagnostics
- International expansion
Threats
- Increasing competition
- Reimbursement challenges
- Regulatory changes
- Technological advancements by competitors
- Economic downturn
Competitors and Market Share
Key Competitors
- FMI
- NTRA
- EXAS
- ILMN
Competitive Landscape
Guardant Health faces competition from both large diagnostic companies and smaller, specialized liquid biopsy firms. Guardant Health's advantages include its comprehensive testing platform and established brand. However, it needs to continue to innovate and expand its product offerings to maintain its market leadership.
Major Acquisitions
Lunit, Inc.
- Year: 2024
- Acquisition Price (USD millions): 0
- Strategic Rationale: Through an alliance with Lunit, GH is seeking to expand the capabilities of data and analytics as well as the combined insights across their diagnostic offerings.
Growth Trajectory and Initiatives
Historical Growth: Data unavailable, needs updated yearly financial data.
Future Projections: Analysts project continued revenue growth for Guardant Health, driven by increasing adoption of its products and expansion into new markets.
Recent Initiatives: Focus on Shield test rollout, expanding partnerships with pharmaceutical companies, and investing in research and development.
Summary
Guardant Health is a leader in the liquid biopsy market with strong offerings for advanced-stage cancer. It aims to expand into early detection, which is a promising but competitive market. High operating expenses and reimbursement challenges remain concerns. Its success hinges on expanding its product offerings and maintaining its market leadership amidst increasing competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Market conditions and company performance can change, impacting the accuracy of this analysis.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Guardant Health Inc
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2018-10-04 | Co-Founder, Co-CEO & Chairman Dr. Helmy Eltoukhy Ph.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 1999 | Website https://guardanthealth.com |
Full time employees 1999 | Website https://guardanthealth.com | ||
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI blood test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for adjuvant treatment and surveillance settings in early-stage cancer patients; and Smart Liquid Biopsy Platform. In addition, the company provides development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.